Medtronic PLC

Medtronic PLC (MDT) Stock Analysis

$91.230

+1.277 (+1.40%)At close

Loading chart…
High
91.560
Open
90.290
VWAP
90.91
Vol
6.47M
Mkt Cap
101.72B
Low
89.940
Amount
588.08M
EV/EBITDA, TTM
11.93

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

www.medtronic.com

AI analysis of Medtronic PLC (MDT)

buy

Medtronic PLC (MDT) is a good buy right now due to its recent strong performance metrics, including a 78% increase in global Cardiac Ablation Solutions revenue and a forward P/E ratio of 15.43, which suggests the stock is undervalued compared to its growth potential. Additionally, hedge funds have increased their buying activity by 167.88% over the last quarter, signaling strong institutional confidence. The main risk is the current market volatility and the potential impact of rising interest rates, as indicated by the Fed's recent comments, which could affect overall market sentiment.

Analyst Ratings (23)

+22.50% upside
Hold
11 Buy
12 Hold
0 Sell
Current: 91.23
Low
102.00
Average
111.76
High
120.00

TD Cowen

2026-08-28

Price Target

$110

Buy

Needham

2026-08-27

Price Target

$114

Buy

UBS

2026-07-28

Price Target

$100

Buy

Evercore ISI

2026-07-06

Price Target

$105

Outperform

BofA

2026-06-12

Price Target

$95

Buy
See All Ratings

Valuation Metrics

The current forward P/E ratio for Medtronic PLC (MDT) is 15.43, compared to its 5-year average forward P/E of 16.25.

Forward P/E

Fair
5Y Average P/E
16.25
Current P/E
15.43
Overvalued
18.20
Undervalued
14.29

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
13.80
Current EV/EBITDA
11.93
Overvalued
15.35
Undervalued
12.25

Forward P/S

Undervalued
5Y Average P/S
3.49
Current P/S
2.86
Overvalued
4.05
Undervalued
2.93

Alphio AI Price Scenarios for MDT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MDT

$89.49

Scenario price

B

Base

Base · 50%MDT

$72.02

Scenario price

B

Bear

Bear · 25%MDT

$70.55

Scenario price

Whales holding MDT

I

Integral Health Asset Management, LLC

+ HoldingMDT

+15.08%

3M Return

B

Burgundy Asset Management Ltd.

+ HoldingMDT

+11.17%

3M Return

E

Equity Investment Corporation

+ HoldingMDT

+10.66%

3M Return

C

Crawford Investment Counsel, Inc.

+ HoldingMDT

+10.17%

3M Return

B

Bellevue Asset Management AG

+ HoldingMDT

+9.20%

3M Return

C

Chilton Investment Company, Inc.

+ HoldingMDT

+8.90%

3M Return

Events Timeline

2026-08-26 (ET)

10:30:00

Canada Raises Tariffs on U.S. Steel and Aluminum to 50%

2026-08-06 (ET)

08:30:00

Medtronic Expands CE Mark Indication for Sphere-9 Catheter

2026-07-16 (ET)

09:30:00

Medtronic Completes Acquisition of SPR Therapeutics for $650M

2026-07-10 (ET)

13:30:00

Leerink Says AMA to Review Renal Denervation Coding Proposal, Positive for Medtronic

Show More Events

News

Show More News

MDT FAQ — answered by Alphio AI

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Medtronic PLC (MDT) is a good buy right now due to its recent strong performance metrics, including a 78% increase in global Cardiac Ablation Solutions revenue and a forward P/E ratio of 15.43, which suggests the stock is undervalued compared to its growth potential. Additionally, hedge funds have increased their buying activity by 167.88% over the last quarter, signaling strong institutional confidence. The main risk is the current market volatility and the potential impact of rising interest rates, as indicated by the Fed's recent comments, which could affect overall market sentiment.

23 analysts cover MDT: 11 rate it Buy, 12 Hold and 0 Sell. The average price target is 111.76.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis